Show simple item record

dc.contributor.authorSmith, David B
dc.contributor.authorHarris, Martin
dc.contributor.authorGowland, Eric
dc.contributor.authorChang, James
dc.contributor.authorScarffe, J Howard
dc.date.accessioned2010-11-09T16:14:11Z
dc.date.available2010-11-09T16:14:11Z
dc.date.issued1986
dc.identifier.citationNon-secretory multiple myeloma: a report of 13 cases with a review of the literature., 4 (4):307-13 Hematol Oncolen
dc.identifier.issn0278-0232
dc.identifier.pmid3549511
dc.identifier.doi10.1002/hon.2900040407
dc.identifier.urihttp://hdl.handle.net/10541/115161
dc.description.abstractThe clinical features of 13 patients with non-secretory myeloma from a series of 172 consecutive multiple myelomas are presented. The non-secretors survived significantly longer that the secretors, median 46 months versus 21 months (p less than 0.01). Non-secretory myeloma was associated with a higher incidence of neurological presentation, minimal lytic bone disease, a lower median percentage of plasma cells in the marrow and a lower incidence of hypogammaglobulinaemia. The median survival of the non-secretors with minimal lytic bone lesions was 74 months compared to 21 months for those with extensive bone disease. The superior survival of non-secretors is thus thought to be due to earlier presentation possibly as a result of a tendency to form symptomatic local tumours. Retrospective immunoperoxidase staining of stored tissue was performed in nine cases. In only one of these was a monoclonal immunoglobulin not detected indicating that true 'non-production' is rare. In four patients who produced a biochemically detectable paraprotein during the course of their disease and in whom immunoperoxidase data was available the immunoglobulin was of the same type. Immunoperoxidase staining may help in the initial diagnosis of non-secretory myeloma but did not contribute any prognostic information.
dc.language.isoenen
dc.subject.meshAdult
dc.subject.meshAged
dc.subject.meshAged, 80 and over
dc.subject.meshBone and Bones
dc.subject.meshFemale
dc.subject.meshHumans
dc.subject.meshImmunoenzyme Techniques
dc.subject.meshKidney
dc.subject.meshMale
dc.subject.meshMiddle Aged
dc.subject.meshMultiple Myeloma
dc.subject.meshMyeloma Proteins
dc.subject.meshPrognosis
dc.subject.meshRetrospective Studies
dc.titleNon-secretory multiple myeloma: a report of 13 cases with a review of the literature.en
dc.typeArticleen
dc.identifier.eissn1099-1069
dc.contributor.departmentCancer Research Campaign Department of Mediacl Oncology, The Christie Hospital and Holt Radium Institute, Manchester M20 9BX, UKen
dc.identifier.journalHematological Oncologyen
html.description.abstractThe clinical features of 13 patients with non-secretory myeloma from a series of 172 consecutive multiple myelomas are presented. The non-secretors survived significantly longer that the secretors, median 46 months versus 21 months (p less than 0.01). Non-secretory myeloma was associated with a higher incidence of neurological presentation, minimal lytic bone disease, a lower median percentage of plasma cells in the marrow and a lower incidence of hypogammaglobulinaemia. The median survival of the non-secretors with minimal lytic bone lesions was 74 months compared to 21 months for those with extensive bone disease. The superior survival of non-secretors is thus thought to be due to earlier presentation possibly as a result of a tendency to form symptomatic local tumours. Retrospective immunoperoxidase staining of stored tissue was performed in nine cases. In only one of these was a monoclonal immunoglobulin not detected indicating that true 'non-production' is rare. In four patients who produced a biochemically detectable paraprotein during the course of their disease and in whom immunoperoxidase data was available the immunoglobulin was of the same type. Immunoperoxidase staining may help in the initial diagnosis of non-secretory myeloma but did not contribute any prognostic information.


This item appears in the following Collection(s)

Show simple item record